HIV/AIDS

New drug outperforms PreP in preventing HIV among African women

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that it is strongly encouraged by new study results showing that the antiretroviral medicine cabotegravir, which is administered by injection every two months, prevents HIV among women. The study shows that the long-acting injections among women in sub-Saharan Africa were 89% more efficient in preventing HIV compared to daily tablets of pre-exposure prophylaxis (PrEP). “These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options

COVID-19’s impact on HIV treatment less severe than originally feared

While recent data collection has shown that the COVID-19 pandemic has had a significant impact on HIV testing services, the impact on HIV treatment is less than originally feared. As of August 2020, the UNAIDS, World Health Organization and United Nations Children’s Fund data collection exercise to identify national, regional and global disruptions of routine HIV services caused by COVID-19 had collected treatment data from 85 countries, of which 22 countries reported data over a sufficient number of months to enable the identification

Drugs for HIV, hepatitis could prevent type 2 diabetes – study

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests. Researchers found that patients taking the drugs had a 33% lower risk of developing diabetes. The scientists say that the risk reduction makes sense based on how the drugs are known to work, and noted that one of the drugs, lamivudine, improved insulin sensitivity significantly in human cell samples and in a mouse model of diabetes. (In type